Utility of 18F-fluoride PET/CT and 18F-FDG PET/CT in the detection of bony metastases in heightened-risk head and neck cancer patients

Journal of Nuclear Medicine

Volumn 53, Issue 11, 2012, Pages 1730-1735

  Chan, Sheng Chieh ^a,b   Wang, Hung Ming ^b   Ng, Shu Hang ^b   Hsu, Cheng Lung ^b   Lin, Yu Jr ^a   Lin, Chien Yu ^b   Liao, Chun Ta ^b   Yen, Tzu Chen ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

18F FDG; 18F fluoride; Bony metastases; Diagnosis; Head and neck cancer; PET

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; SODIUM FLUORIDE F 18; DIAGNOSTIC AGENT; FLUORIDE; RADIOACTIVE IODINE;

ARTICLE; BONE METASTASIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; BONE TUMOR; CLINICAL TRIAL; HEAD AND NECK TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RISK; SCINTISCANNING;

BONE NEOPLASMS; FLUORIDES; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RISK; SENSITIVITY AND SPECIFICITY;

EID: 84868321340     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.104893     Document Type: Article

References (19)

1. Ferlito A, Shaha AR, Silver CE, Rinaldo A, Mondin V. Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:202-207.
2. 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68-78.
3. 18FFDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1807-1812.
4. 18F PET. J Nucl Med. 1999;40:1623-1629.
5. 18F-fluoride PET/CT. J Nucl Med. 2006;47:287-297.
6. 99mTc-MDP bone scintigraphy for the detection of bone metastases in cancer patients. Nucl Med Commun. 2010;31:597-603.
7. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375-3379.
8. 18FDGPET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol. 2011;40:523-531.
9. 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol. 2011;21:2604-2617.
10. 18F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: a comparative study. Eur J Nucl Med Mol Imaging. 2011;38:1607-1619.
11. 18F-FDG PET and extended-field multi-detector row CT. Neuroradiology. 2008;50:969-979.
12. Krasnow AZ, Hellman RS, Timins ME, Collier BD, Anderson T, Isitman AT. Diagnostic bone scanning in oncology. Semin Nucl Med. 1997;27:107-141.
13. 18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2006;24:599-604.
14. Newton TH, Potts DG. Computed Tomography of the Spine and Spinal Cord. San Anselmo, CA: Clavadel Press; 1983:160-163.
15. 18F-fluoride PET/CT. J Nucl Med. 2004;45:272-278.
16. Yen RF, Chen CY, Cheng MF, et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun. 2010;31:637-645.
17. Galasko CS. Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop Relat Res. 1982;169:20-27.
18. Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253-1258.
19. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun. 2011;32:168-176.